Wave Life Sciences, Inc. (WVE) earnings date
Mar 3, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 14 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Oct 27, 2026 | before open | 27 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Tue, Apr 28, 2026 | before open | 28 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | before open | 41 | 8-K |
| Q2 FY2025 | Wed, Jul 30, 2025 | before open | 30 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Tue, Mar 4, 2025 | before open | 63 | 8-K |
What they guided beta
| Q3 FY2026 | "Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment settings: dosing ongoing in Phase 2a monotherapy clinical trial in individuals with higher BMI and comorbidities, initiated Phase 2a combination trial, and remain on track to initiate post-incretin maintenance trial this quarter CTA submission for WVE-008 for PNPLA3 liver disease (RNA editing" exhibit |
| Q3 FY2026 | "We also remain on track to initiate a post-incretin maintenance trial of WVE-007 in the fourth quarter that has the potential to unlock an entirely new frontier in obesity by enabling patients an off-ramp for their incretin therapy.”" exhibit |
| Q3 FY2026 | "Wave expects to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Wave remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy to preserve weight loss following discontinuation of incretin treatment in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Wave expects to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007’s potential in MASH, type 2 diabetes, and other cardiometabolic diseases Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026 FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA edit" exhibit |
| Q2 FY2026 | "Additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026." exhibit |
| Q2 FY2026 | "Combination with incretin and post-incretin maintenance: Wave expects to initiate Phase 2 trials of WVE-007 in the combination and maintenance settings in the second half of 2026." exhibit |
| Q2 FY2026 | "Wave expects to share data from the 600 mg (monthly) multidose cohort in the second half of 2026." exhibit |
| Q2 FY2026 | "Investor Day 2026: Wave plans to host an investor day in the fall of 2026, where the company expects to share updates from its clinical and preclinical pipeline of RNA medicines." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/WVE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/WVE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/WVE/"><img src="https://veritasdata.dev/embed/WVE.svg" alt="WVE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/WVE/)
Script
<script async src="https://veritasdata.dev/embed/WVE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/WVE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.